Global Information
회사소개 | 문의 | 비교리스트

세계의 위장관질환 치료제 시장(2020-2024년)

Global Gastrointestinal Diseases Therapeutics Market 2020-2024

리서치사 TechNavio (Infiniti Research Ltd.)
발행일 2020년 04월 상품 코드 934845
페이지 정보 영문 120 Pages
가격
US $ 2,500 ₩ 3,002,000 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,000 ₩ 3,603,000 PDF by E-mail (5-user License) help
동일 사업장 내 5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,804,000 PDF by E-mail (Enterprise License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 6,005,000 PDF by E-mail (Global License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다. 또한 해당 라이선스는 보고서 컨텐츠의 15% 이내로 외부용 문서에 인용 게재가 허용됩니다(예:프레스릴리스, 마케팅 자료, 백서 등).


세계의 위장관질환 치료제 시장(2020-2024년) Global Gastrointestinal Diseases Therapeutics Market 2020-2024
발행일 : 2020년 04월 페이지 정보 : 영문 120 Pages

세계의 위장관질환 치료제 시장은 2020-2024년간의 예측기간 동안 9%의 연평균 복합 성장률(CAGR)로 성장을 지속하여 228억 2,000만 달러 규모에 달할 전망입니다. 위장관질환 발생률 증가, 신약 출시 및 생물제제와 표적치료 수요 등이 시장 성장 주요인입니다.

세계의 위장관질환 치료(Gastrointestinal Diseases Therapeutics) 시장에 대해 조사 분석했으며, 시장 규모 및 성장률, 시장 동향, 시장 성장 촉진요인, 과제, 시장 기회 분석, 주요 벤더 등에 대한 체계적인 정보를 전해드립니다.

목차

개요

시장 상황

시장 규모

  • 시장 정의
  • 시장 부문 분석
  • 시장 규모(2019년)
  • 시장 전망 : 예측(2019-2024년)

Five Forces 분석

약제 클래스별 시장 세분화

  • 시장 세분화
  • 약제 클래스별 비교 : 시장 규모 예측(2019-2024년)
  • 항염증제와 면역억제제
  • 산중화제
  • 기타 치료제
  • 약제 클래스별 시장 기회

고객 상황

지역별 상황

  • 지역별 세분화
  • 지역별 비교 : 시장 규모 예측(2019-2024년)
  • 북미
  • 유럽
  • 아시아
  • 기타 지역
  • 주요 국가
  • 지역별 시장 기회
  • 수량 성장요인 - 수요 중심 성장
  • 시장의 과제
  • 시장 동향

벤더 상황

  • 개요
  • 벤더 상황
  • 파괴적 혁신
  • 산업 리스크

벤더 분석

  • 대상 벤더
  • 벤더의 시장 포지셔닝
  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca Plc
  • Bausch Health Companies Inc.
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • UCB SA

부록

LSH 20.05.15

Technavio has been monitoring the gastrointestinal diseases therapeutics market and it is poised to grow by $ 22.82 bn during 2020-2024 progressing at a CAGR of 9% during the forecast period. Our reports on gastrointestinal diseases therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the increasing incidence of gastrointestinal diseases, new product launches, and demand for biologics and targeted therapies. In addition, increasing incidence of gastrointestinal diseases is anticipated to boost the growth of the market as well.

The gastrointestinal diseases therapeutics market analysis includes drug class segment and geographic landscapes

Technavio's ‘ gastrointestinal diseases therapeutics market ’ is segmented as below:

By Drug Class

  • Anti-inflammatory and immunosuppressors
  • Acid neutralizers
  • Other therapeutics

By Geographic Landscape:

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the strong product pipeline as one of the prime reasons driving the gastrointestinal diseases therapeutics market growth during the next few years. Also, funding for gastrointestinal research studies, and increase in self-medication coupled with home-based therapies will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our gastrointestinal diseases therapeutics market covers the following areas:

  • Gastrointestinal diseases therapeutics market sizing
  • Gastrointestinal diseases therapeutics market forecast
  • Gastrointestinal diseases therapeutics market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading gastrointestinal diseases therapeutics market vendors that include Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Takeda Pharmaceutical Co. Ltd., and UCB SA. Also, the gastrointestinal diseases therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Drug class

  • Market segments
  • Comparison by Drug class
  • Anti-inflammatory and immunosuppressors - Market size and forecast 2019-2024
  • Acid neutralizers - Market size and forecast 2019-2024
  • Other therapeutics - Market size and forecast 2019-2024
  • Market opportunity by Drug class

Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Volume driver - Demand led growth
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Vendor landscape
  • Landscape disruption
  • Industry risks

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca Plc
  • Bausch Health Companies Inc.
  • Boehringer Ingelheim International GmbH
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • UCB SA

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2019 - 2024 ($ billion)
  • 13: Global market: Year-over-year growth 2019 - 2024 (%)
  • 14: Five forces analysis 2019 & 2024
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2019
  • 21: Other1 - Market share 2019-2024 (%)
  • 22: Comparison by Other1
  • 23: Anti-inflammatory and immunosuppressors - Market size and forecast 2019-2024 ($ billion)
  • 24: Anti-inflammatory and immunosuppressors - Year-over-year growth 2019-2024 (%)
  • 25: Acid neutralizers - Market size and forecast 2019-2024 ($ billion)
  • 26: Acid neutralizers - Year-over-year growth 2019-2024 (%)
  • 27: Other therapeutics - Market size and forecast 2019-2024 ($ billion)
  • 28: Other therapeutics - Year-over-year growth 2019-2024 (%)
  • 29: Market opportunity by Other1
  • 30: Customer landscape
  • 31: Market share by geography 2019-2024 (%)
  • 32: Geographic comparison
  • 33: North America - Market size and forecast 2019-2024 ($ billion)
  • 34: North America - Year-over-year growth 2019-2024 (%)
  • 35: Europe - Market size and forecast 2019-2024 ($ billion)
  • 36: Europe - Year-over-year growth 2019-2024 (%)
  • 37: Asia - Market size and forecast 2019-2024 ($ billion)
  • 38: Asia - Year-over-year growth 2019-2024 (%)
  • 39: ROW - Market size and forecast 2019-2024 ($ billion)
  • 40: ROW - Year-over-year growth 2019-2024 (%)
  • 41: Key leading countries
  • 42: Market opportunity by geography ($ billion)
  • 43: Impact of drivers and challenges
  • 44: Vendor landscape
  • 45: Landscape disruption
  • 46: Industry risks
  • 47: Vendors covered
  • 48: Market positioning of vendors
  • 49: Abbott Laboratories - Overview
  • 50: Abbott Laboratories - Business segments
  • 51: Abbott Laboratories - Key offerings
  • 52: Abbott Laboratories - Key customers
  • 53: Abbott Laboratories - Segment focus
  • 54: AbbVie Inc. - Overview
  • 55: AbbVie Inc. - Business segments
  • 56: AbbVie Inc. - Key offerings
  • 57: AbbVie Inc. - Key customers
  • 58: AbbVie Inc. - Segment focus
  • 59: AstraZeneca Plc - Overview
  • 60: AstraZeneca Plc - Business segments
  • 61: AstraZeneca Plc - Key offerings
  • 62: AstraZeneca Plc - Key customers
  • 63: AstraZeneca Plc - Segment focus
  • 64: Bausch Health Companies Inc. - Overview
  • 65: Bausch Health Companies Inc. - Business segments
  • 66: Bausch Health Companies Inc. - Key offerings
  • 67: Bausch Health Companies Inc. - Key customers
  • 68: Bausch Health Companies Inc. - Segment focus
  • 69: Boehringer Ingelheim International GmbH - Overview
  • 70: Boehringer Ingelheim International GmbH - Business segments
  • 71: Boehringer Ingelheim International GmbH - Key offerings
  • 72: Boehringer Ingelheim International GmbH - Key customers
  • 73: Boehringer Ingelheim International GmbH - Segment focus
  • 74: GlaxoSmithKline Plc - Overview
  • 75: GlaxoSmithKline Plc - Business segments
  • 76: GlaxoSmithKline Plc - Key offerings
  • 77: GlaxoSmithKline Plc - Key customers
  • 78: GlaxoSmithKline Plc - Segment focus
  • 79: Johnson & Johnson - Overview
  • 80: Johnson & Johnson - Business segments
  • 81: Johnson & Johnson - Key offerings
  • 82: Johnson & Johnson - Key customers
  • 83: Johnson & Johnson - Segment focus
  • 84: Merck & Co. Inc. - Overview
  • 85: Merck & Co. Inc. - Business segments
  • 86: Merck & Co. Inc. - Key offerings
  • 87: Merck & Co. Inc. - Key customers
  • 88: Merck & Co. Inc. - Segment focus
  • 89: Takeda Pharmaceutical Co. Ltd. - Overview
  • 90: Takeda Pharmaceutical Co. Ltd. - Product and service
  • 91: Takeda Pharmaceutical Co. Ltd. - Key offerings
  • 92: Takeda Pharmaceutical Co. Ltd. - Key customers
  • 93: Takeda Pharmaceutical Co. Ltd. - Segment focus
  • 94: UCB SA - Overview
  • 95: UCB SA - Business segments
  • 96: UCB SA - Key offerings
  • 97: UCB SA - Key customers
  • 98: UCB SA - Segment focus
  • 99: Currency conversion rates for US$
  • 100: Research Methodology
  • 101: Validation techniques employed for market sizing
  • 102: Information sources
  • 103: List of abbreviations
Back to Top
전화 문의
F A Q